|InPoint Q3 2023 Stockholder Letter||10/10/2023|
|Recommendation to Reject Mackenzie Offer||09/08/2023|
|InPoint Q4 2022 Stockholder Letter||01/10/2023|
|InPoint October Distribution Stockholder Letter||10/08/2021|
|InPoint April Distribution Stockholder Letter||4/07/2021|
|InPoint October Distribution Stockholder Letter||11/06/2020|
|InPoint Q3 2020 Stockholder Letter||10/07/2020|
|InPoint August Distribution Stockholder Letter||9/02/2020|
|InPoint Distribution Reinstatement Stockholder Letter||8/05/2020|
|InPoint COVID-19 Update Stockholder Letter||7/20/2020|
|InPoint COVID-19 Update Stockholder Letter||6/15/2020|
|InPoint COVID-19 Update Stockholder Letter||4/30/2020|
|InPoint COVID-19 Update Stockholder Letter||3/27/2020|
|InPoint Q4 2019 Stockholder Letter||1/09/2020|
This website is neither an offer to sell nor a solicitation of an offer to buy securities. An offering is made only by the prospectus. This material must be read in conjunction with the prospectus in order to fully understand all of the implications and risks of the offering of securities to which the prospectus relates. A copy of the prospectus must be made available to you in connection with any offering. No offering is made except by a prospectus filed with the Department of Law of the State of New York. Neither the Securities and Exchange Commission, the Attorney-General of the State of New York nor any other state securities regulator has approved or disapproved of the securities, determined if the prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
This website contains forward-looking statements that are subject to risks and uncertainties. Please see "Risk Factors" for additional information.